https://news.medxy.ai/zh/escc-pd-l1-therapy/Medxy AIzh2026-09-22T07:46:42-07:00解码细胞互作，提升食管鳞状细胞癌新辅助PD-L1阻断疗效 https://news.medxy.ai/ja/pd-l1-therapy-response/Medxy AIja2026-09-22T07:46:26-07:00食道扁平上皮癌における術前PD-L1遮断療法の反応を読み解く細胞間相互作用 https://news.medxy.ai/vi/cell-interaction-pd-l1/Medxy AIvi2026-09-22T07:46:06-07:00Giải mã tương tác tế bào để tăng cường đáp ứng ức chế PD-L1 tân bổ trợ trong ung thư biểu mô tế bào vảy thực quản https://news.medxy.ai/decoding-cellular-interactions-to-enhance-neoadjuvant-pd-l1-blockade-response-in-esophageal-squamous-cell-carcinoma/Medxy AIen2026-09-22T07:45:48-07:00Decoding Cellular Interactions to Enhance Neoadjuvant PD-L1 Blockade Response in Esophageal Squamous Cell Carcinoma https://news.medxy.ai/zh/carotid-dissection-stroke/Medxy AIzh2026-09-22T07:45:14-07:00颅颈动脉夹层后卒中复发的时间规律与形态学预测因素 https://news.medxy.ai/ja/stroke-recurrence-after-dissection/Medxy AIja2026-09-22T07:44:57-07:00頭蓋頸部動脈解離後の脳卒中再発：時間的推移と画像形態による予測因子 https://news.medxy.ai/vi/stroke-recurrence-prediction-5/Medxy AIvi2026-09-22T07:44:36-07:00Động học theo thời gian và các yếu tố hình thái dự báo tái phát đột quỵ sau bóc tách động mạch sọ-cổ https://news.medxy.ai/temporal-dynamics-and-morphological-predictors-of-stroke-recurrence-after-craniocervical-artery-dissection/Medxy AIen2026-09-22T07:44:16-07:00Temporal Dynamics and Morphological Predictors of Stroke Recurrence After Craniocervical Artery Dissection https://news.medxy.ai/zh/cushing-syndrome-lipid-worsening-2/Medxy AIzh2026-09-22T07:43:42-07:00库欣综合征术后早期血脂反常恶化：对心血管风险管理的启示 https://news.medxy.ai/ja/cushing-syndrome-lipid-worsening/Medxy AIja2026-09-22T07:43:25-07:00クッシング症候群の術後早期にみられる脂質悪化：心血管リスク評価と管理への示唆 https://news.medxy.ai/vi/cushing-syndrome-lipids/Medxy AIvi2026-09-22T07:43:05-07:00Hội chứng Cushing: Rối loạn lipid có thể nặng hơn sớm sau mổ và hàm ý nguy cơ tim mạch https://news.medxy.ai/early-lipid-deterioration/Medxy AIen2026-09-22T07:42:46-07:00Unexpected Early Postoperative Lipid Deterioration in Cushing’s Syndrome: Implications for Cardiovascular Risk and Management https://news.medxy.ai/ja/gene-editing-cvd/Medxy AIja2026-09-22T07:42:12-07:00心血管疾患における遺伝子編集療法：2026年ACC声明の重要ポイント https://news.medxy.ai/vi/76924-2/Medxy AIvi2026-09-22T07:41:38-07:00Các liệu pháp chỉnh sửa gen cho bệnh tim mạch: Những điểm chính từ Tuyên bố Khoa học năm 2026 của ACC https://news.medxy.ai/zh/cardiovascular-gene-editing/Medxy AIzh2026-09-22T07:41:02-07:00心血管疾病基因编辑治疗：2026 年 ACC 科学声明要点解读 https://news.medxy.ai/gene-editing-therapy-in-cardiovascular-disease-key-takeaways-from-the-2026-acc-scientific-statement/Medxy AIen2026-09-22T07:40:28-07:00Gene Editing Therapy in Cardiovascular Disease: Key Takeaways from the 2026 ACC Scientific Statement https://news.medxy.ai/zh/veteran-intimate-partner-violence/Medxy AIzh2026-09-22T07:34:45-07:00破解退伍军人亲密伴侣暴力医法合作落地难题：来自VA的启示 https://news.medxy.ai/ja/intimate-partner-violence/Medxy AIja2026-09-22T07:34:27-07:00親密なパートナー間暴力を経験する退役軍人への医療-法的連携を阻む壁を越えて：VAからの示唆 https://news.medxy.ai/vi/76913-2/Medxy AIvi2026-09-22T07:34:06-07:00Các vấn đề y tế liên quan đến bạo lực từ bạn tình ở cựu chiến binh https://news.medxy.ai/overcoming-barriers-to-medical-legal-partnerships-for-veterans-experiencing-intimate-partner-violence-insights-from-the-va/Medxy AIen2026-09-22T07:33:45-07:00Overcoming Barriers to Medical-Legal Partnerships for Veterans Experiencing Intimate Partner Violence: Insights from the VA https://news.medxy.ai/zh/dapirolizumab-sle-study/Medxy AIzh2026-09-22T05:41:33-07:00Dapirolizumab Pegol 改善系统性红斑狼疮疾病活动度：来自 PHOENYCS GO Ⅲ期试验及既往研究的证据 https://news.medxy.ai/ja/76203-2/Medxy AIja2026-09-22T05:41:05-07:00ダピロリズマブ・ペゴルによる全身性エリテマトーデスの疾患活動性の改善：PHOENYCS GO第III相試験および過去の研究からのエビデンス https://news.medxy.ai/vi/dapirolizumab-lupus/Medxy AIvi2026-09-22T05:40:27-07:00Dapirolizumab Pegol cải thiện hoạt tính bệnh ở lupus ban đỏ hệ thống: bằng chứng từ thử nghiệm pha 3 PHOENYCS GO và các nghiên cứu trước đó https://news.medxy.ai/dapirolizumab-pegol-improves-disease-activity-in-systemic-lupus-erythematosus-evidence-from-phase-3-phoenycs-go-trial-and-prior-studies/Medxy AIen2026-09-22T05:39:58-07:00Dapirolizumab Pegol Improves Disease Activity in Systemic Lupus Erythematosus: Evidence from Phase 3 PHOENYCS GO Trial and Prior Studies https://news.medxy.ai/zh/gvhd-prevention-evolution/Medxy AIzh2026-09-22T05:36:55-07:00alloHSCT中GVHD预防的演变：来自西班牙大型真实世界队列的启示 https://news.medxy.ai/ja/gvhd-prevention-evolution-2/Medxy AIja2026-09-22T05:36:33-07:00同種造血幹細胞移植におけるGVHD予防の進化：スペイン大規模実臨床コホートからの示唆 https://news.medxy.ai/vi/gvhd-prophylaxis-allohsct/Medxy AIvi2026-09-22T05:36:09-07:00Dự phòng GVHD trong alloHSCT đang thay đổi: Góc nhìn từ một đoàn hệ thực tế quy mô lớn tại Tây Ban Nha https://news.medxy.ai/evolving-gvhd-prophylaxis-in-allohsct-insights-from-a-large-real-world-spanish-cohort/Medxy AIen2026-09-22T05:35:47-07:00Evolving GVHD Prophylaxis in AlloHSCT: Insights from a Large Real-World Spanish Cohort https://news.medxy.ai/zh/car-t-lymphoma-risks/Medxy AIzh2026-09-22T05:35:05-07:00揭示隐藏风险：CAR T细胞治疗后T细胞淋巴瘤——罕见但真实存在的隐忧 https://news.medxy.ai/ja/car-t-therapy-risks/Medxy AIja2026-09-22T05:34:43-07:00CAR T細胞療法後に潜む稀なリスク――T細胞リンパ腫を読み解く https://news.medxy.ai/vi/car-t-cell-therapy-risks/Medxy AIvi2026-09-22T05:34:18-07:00Hiểu rõ nguy cơ: U lympho tế bào T sau liệu pháp CAR T-cell therapy — mối lo hiếm gặp nhưng có thật https://news.medxy.ai/t-cell-lymphoma-risks/Medxy AIen2026-09-22T05:33:53-07:00Unraveling the Risks: T-Cell Lymphoma After CAR T-Cell Therapy—A Rare but Real Concern https://news.medxy.ai/zh/real-world-evidence-myeloma/Medxy AIzh2026-09-22T05:33:04-07:00全球真实世界证据：多发性骨髓瘤自体干细胞移植后维持治疗可带来生存获益 https://news.medxy.ai/ja/76183-2/Medxy AIja2026-09-22T05:32:42-07:00多発性骨髄腫における自家幹細胞移植後の維持療法は、生存上の利益をもたらす可能性がある https://news.medxy.ai/vi/stem-cell-transplant-survival/Medxy AIvi2026-09-22T05:32:20-07:00Bằng chứng thực tế toàn cầu cho thấy điều trị duy trì sau ghép tế bào gốc tự thân cải thiện sống còn ở đa u tủy https://news.medxy.ai/global-real-world-evidence-shows-survival-benefit-of-maintenance-therapy-post-autologous-stem-cell-transplant-in-multiple-myeloma/Medxy AIen2026-09-22T05:31:58-07:00Global Real-World Evidence Shows Survival Benefit of Maintenance Therapy Post-Autologous Stem Cell Transplant in Multiple Myeloma https://news.medxy.ai/zh/ai-fibrosis-diagnosis/Medxy AIzh2026-09-22T05:29:36-07:00AI赋能骨髓纤维化诊断：Continuous Indexing of Fibrosis（CIF）的临床评估 https://news.medxy.ai/ja/ai-fibrosis-diagnosis-2/Medxy AIja2026-09-22T05:29:15-07:00骨髄線維化診断を高精度化：AI駆動型Continuous Indexing of Fibrosis（CIF）の臨床評価 https://news.medxy.ai/vi/bone-marrow-fibrosis-diagnosis/Medxy AIvi2026-09-22T05:28:52-07:00Nâng cao chẩn đoán xơ hóa tủy xương: Đánh giá lâm sàng chỉ số liên tục xơ hóa do AI hỗ trợ (CIF) https://news.medxy.ai/enhancing-bone-marrow-fibrosis-diagnosis-clinical-evaluation-of-ai-driven-continuous-indexing-of-fibrosis-cif/Medxy AIen2026-09-22T05:28:26-07:00Enhancing Bone Marrow Fibrosis Diagnosis: Clinical Evaluation of AI-Driven Continuous Indexing of Fibrosis (CIF) https://news.medxy.ai/zh/76169-2/Medxy AIzh2026-09-22T05:27:46-07:00靶向IL-17A驱动的PTGS2/NLRP3炎性小体活性：针对PTPN11突变型JMML的新治疗策略 https://news.medxy.ai/ja/il-17a-ptgs2-nlrp3-targeting/Medxy AIja2026-09-22T05:27:21-07:00IL-17A駆動のPTGS2/NLRP3インフラマソーム活性を標的化：PTPN11変異JMMLに対する新たな治療戦略 https://news.medxy.ai/vi/il-17a-ptpn11-treatment/Medxy AIvi2026-09-22T05:26:53-07:00Nhắm trúng trục IL-17A thúc đẩy hoạt hóa PTGS2/NLRP3: hướng điều trị mới trong JMML đột biến PTPN11 https://news.medxy.ai/targeting-il-17a-driven-ptgs2-nlrp3-inflammasome-activation-a-novel-therapeutic-approach-in-ptpn11-mutant-juvenile-myelomonocytic-leukemia/Medxy AIen2026-09-22T05:26:27-07:00Targeting IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation: A Novel Therapeutic Approach in PTPN11-Mutant Juvenile Myelomonocytic Leukemia https://news.medxy.ai/zh/target-pkmyt1/Medxy AIzh2026-09-22T05:25:36-07:00靶向PKMYT1：高危del(17p)多发性骨髓瘤的潜在治疗新策略 https://news.medxy.ai/ja/pkmyt1-targeting/Medxy AIja2026-09-22T05:25:16-07:00PKMYT1を標的にする：del(17p)高リスク多発性骨髄腫に対する有望な治療戦略 https://news.medxy.ai/vi/target-pkmyt1-2/Medxy AIvi2026-09-22T05:24:52-07:00Nhắm vào PKMYT1: Chiến lược điều trị đầy hứa hẹn cho đa u tủy nguy cơ cao del(17p) https://news.medxy.ai/targeting-pkmyt1-a-promising-therapeutic-strategy-for-high-risk-del17p-multiple-myeloma/Medxy AIen2026-09-22T05:24:29-07:00Targeting PKMYT1: A Promising Therapeutic Strategy for High-Risk del(17p) Multiple Myeloma https://news.medxy.ai/zh/ibrutinib-venetoclax-lymphoma/Medxy AIzh2026-09-22T05:23:40-07:00老年及TP53突变非母细胞样套细胞淋巴瘤的一线伊布替尼联合维奈克拉：疗效与安全性 https://news.medxy.ai/ja/ibrutinib-benetoclax-treatment/Medxy AIja2026-09-22T05:23:18-07:00非芽球様マントル細胞リンパ腫に対するイブルチニブ＋ベネトクラクス一次治療：高齢者およびTP53変異例における有効性と安全性 https://news.medxy.ai/vi/ibrutinib-venetoclax-lymphoma-2/Medxy AIvi2026-09-22T05:22:53-07:00Ibrutinib phối hợp Venetoclax ở tuyến đầu cho u lympho tế bào áo thể không blastoid: Hiệu quả và độ an toàn ở người cao tuổi và bệnh nhân mang đột biến TP53 https://news.medxy.ai/first-line-ibrutinib-plus-venetoclax-in-nonblastoid-mantle-cell-lymphoma-efficacy-and-safety-in-older-adults-and-tp53-mutant-patients/Medxy AIen2026-09-22T05:22:28-07:00First-line Ibrutinib Plus Venetoclax in Nonblastoid Mantle Cell Lymphoma: Efficacy and Safety in Older Adults and TP53-Mutant Patients https://news.medxy.ai/zh/lung-transplant-kidney-impact/Medxy AIzh2026-09-22T05:21:40-07:002023年安全网政策对肺移植后肾移植的影响：移植实践与结局的早期变化 https://news.medxy.ai/ja/safety-net-impact-transplant/Medxy AIja2026-09-22T05:21:21-07:002023年safety net policyが肺移植後腎移植に与えた影響：移植診療と転帰の早期変化 https://news.medxy.ai/vi/safety-net-impact/Medxy AIvi2026-09-22T05:20:57-07:00Tác động của chính sách “safety net” năm 2023 đối với ghép thận sau ghép phổi: Những thay đổi sớm trong thực hành ghép và kết cục https://news.medxy.ai/impact-of-the-2023-safety-net-policy-on-kidney-after-lung-transplantation-early-changes-in-transplant-practices-and-outcomes/Medxy AIen2026-09-22T05:20:32-07:00Impact of the 2023 Safety Net Policy on Kidney After Lung Transplantation: Early Changes in Transplant Practices and Outcomes https://news.medxy.ai/zh/dupilumab-asthma-effects/Medxy AIzh2026-09-22T05:19:46-07:00CT视角下度普利尤单抗对中重度哮喘黏液栓动态及放射密度的影响 https://news.medxy.ai/ja/mucus-plug-dupilumab-effects/Medxy AIja2026-09-22T05:19:24-07:00中等症から重症喘息における粘液栓の変化と放射線濃度へのデュピルマブの影響：CT画像からみた解析 https://news.medxy.ai/vi/dupilumab-asthma-ct-2/Medxy AIvi2026-09-22T05:19:02-07:00Tác động của Dupilumab lên động học nút nhầy và mật độ tia X trong hen phế quản mức độ trung bình đến nặng: góc nhìn từ chẩn đoán hình ảnh CT https://news.medxy.ai/dupilumab-asthma-ct/Medxy AIen2026-09-22T05:18:37-07:00Dupilumab’s Impact on Mucus Plug Dynamics and Radiodensity in Moderate to Severe Asthma: A CT Imaging Perspective https://news.medxy.ai/zh/lung-cancer-screening-quality/Medxy AIzh2026-09-22T05:17:52-07:00远程医疗与面对面沟通下肺癌筛查共享决策质量：患者感知、证据综述与临床启示 https://news.medxy.ai/ja/76143-2/Medxy AIja2026-09-22T05:17:31-07:00遠隔医療と対面診療における肺がん検診の共有意思決定の質 https://news.medxy.ai/vi/patient-awareness-shared-decision-making/Medxy AIvi2026-09-22T05:17:02-07:00Nhận thức của bệnh nhân về chất lượng ra quyết định chung trong tầm soát ung thư phổi: so sánh giữa tư vấn từ xa và trao đổi trực tiếp, tổng hợp bằng chứng và góc nhìn lâm sàng https://news.medxy.ai/patient-perceptions-of-quality-of-shared-decision-making-for-lung-cancer-screening-in-telehealth-vs-in-person-discussions-a-synthesis-of-evidence-and-clinical-insights/Medxy AIen2026-09-22T05:16:37-07:00Patient Perceptions of Quality of Shared Decision-Making for Lung Cancer Screening in Telehealth vs In-Person Discussions: A Synthesis of Evidence and Clinical Insights https://news.medxy.ai/zh/bridging-eye-care-gap/Medxy AIzh2026-09-22T05:15:37-07:00弥合视力照护鸿沟：基于 CFIR 的美国社区成人眼筛查研究启示 https://news.medxy.ai/ja/ophthalmology-screening-challenges/Medxy AIja2026-09-22T05:15:14-07:00地域眼科スクリーニングの課題をどう越えるか：米国のCFIRガイド研究が示す示唆 https://news.medxy.ai/vi/eye-care-gap/Medxy AIvi2026-09-22T05:14:42-07:00Thu hẹp khoảng cách trong chăm sóc thị lực: Những phát hiện từ nghiên cứu định hướng CFIR về sàng lọc mắt cho người lớn dựa vào cộng đồng tại Hoa Kỳ https://news.medxy.ai/bridging-the-gap-in-vision-care-insights-from-a-cfir-guided-study-on-community-based-adult-eye-screening-in-the-u-s/Medxy AIen2026-09-22T05:14:16-07:00Bridging the Gap in Vision Care: Insights from a CFIR-Guided Study on Community-Based Adult Eye Screening in the U.S. https://news.medxy.ai/zh/76134-2/Medxy AIzh2026-09-22T05:13:30-07:00眼睑下垂综合征（Sagging Eye Syndrome）术后上斜视复发的研究 https://news.medxy.ai/ja/sagging-eye-syndrome/Medxy AIja2026-09-22T05:13:07-07:00Sagging Eye Syndromeにおける術後hypertropia再発の長期経過：知見と臨床的含意 https://news.medxy.ai/vi/76132-2/Medxy AIvi2026-09-22T05:12:41-07:00Diễn tiến dài hạn của tình trạng tái phát lác đứng lên (hypertropia) sau phẫu thuật ở bệnh nhân mắc hội chứng mắt xệ (Sagging Eye Syndrome) https://news.medxy.ai/long-term-recurrence-of-hypertropia-after-surgery-in-sagging-eye-syndrome-insights-and-implications/Medxy AIen2026-09-22T05:12:15-07:00Long-Term Recurrence of Hypertropia After Surgery in Sagging Eye Syndrome: Insights and Implications https://news.medxy.ai/zh/76129-2/Medxy AIzh2026-09-22T05:11:28-07:00超广角OCT揭示了伴有后巩膜葡萄肿的病理性近视中中央凹陷的形态及视神经乳头的特征 https://news.medxy.ai/ja/76128-2/Medxy AIja2026-09-22T05:11:04-07:00広範囲UWF-OCTが明らかにする、後部強膜ブリージアを伴う病的近視における黄斑部および視神経乳頭の形態的特徴 https://news.medxy.ai/vi/uwf-oct-central-nerve/Medxy AIvi2026-09-22T05:10:38-07:00UWF-OCT trường siêu rộng hé lộ địa hình hố trung tâm và đầu dây thần kinh thị giác khác biệt trong cận thị bệnh lý kèm phình lồi củng mạc sau https://news.medxy.ai/ultra-widefield-oct-reveals-distinct-foveal-and-optic-nerve-head-topography-in-pathologic-myopia-with-posterior-staphyloma/Medxy AIen2026-09-22T05:10:13-07:00Ultra-Widefield OCT Reveals Distinct Foveal and Optic Nerve Head Topography in Pathologic Myopia with Posterior Staphyloma https://news.medxy.ai/zh/pcv-treatment-outcomes/Medxy AIzh2026-09-22T05:09:27-07:00PCV完全消退后按需阿柏西普治疗的结局：临床综述 https://news.medxy.ai/ja/aflibercept-treatment-outcomes/Medxy AIja2026-09-22T05:09:02-07:00ポリープ状脈絡膜血管症における完全退縮後の必要時アフリベルセプト治療の転帰：臨床レビュー https://news.medxy.ai/vi/76122-2/Medxy AIvi2026-09-22T05:08:34-07:00Kết quả điều trị bằng aflibercept theo nhu cầu sau khi bệnh lý mạch hắc mạc đa giác (PCV) đã thoái lui hoàn toàn https://news.medxy.ai/outcomes-of-as-needed-aflibercept-treatment-after-complete-regression-in-polypoidal-choroidal-vasculopathy-a-clinical-review/Medxy AIen2026-09-22T05:08:02-07:00Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy: A Clinical Review https://news.medxy.ai/zh/76119-2/Medxy AIzh2026-09-22T05:07:08-07:00舒马曲坦（Susetiridine）能减少头颈部手术后阿片类药物使用 https://news.medxy.ai/ja/suzoterijin-opioid-use/Medxy AIja2026-09-22T05:06:48-07:00頭頸部手術後のオピオイド使用を抑えるスゼトリジンの役割：後ろ向きコホート解析 https://news.medxy.ai/vi/opioid-reduction-surgery/Medxy AIvi2026-09-22T05:06:25-07:00Suzetrigine giúp giảm sử dụng opioid sau phẫu thuật đầu cổ như thế nào? Phân tích đoàn hệ hồi cứu https://news.medxy.ai/suzetrigines-role-in-reducing-opioid-use-after-head-and-neck-surgery-a-retrospective-cohort-analysis/Medxy AIen2026-09-22T05:06:03-07:00Suzetrigine’s Role in Reducing Opioid Use After Head and Neck Surgery: A Retrospective Cohort Analysis https://news.medxy.ai/zh/rf-ablation-thyroid-nodules/Medxy AIzh2026-09-22T05:05:19-07:00射频消融：甲状腺叶切除术后甲状腺结节的微创替代方案 https://news.medxy.ai/ja/radiofrequency-ablation-options/Medxy AIja2026-09-22T05:05:00-07:00葉切除後の甲状腺結節に対する低侵襲選択肢：Radiofrequency Ablationの有用性 https://news.medxy.ai/vi/radiofrequency-ablation/Medxy AIvi2026-09-22T05:04:38-07:00Đốt sóng cao tần: Lựa chọn ít xâm lấn cho nhân giáp sau cắt thùy giáp https://news.medxy.ai/radiofrequency-ablation-a-minimally-invasive-alternative-for-thyroid-nodules-post-lobectomy/Medxy AIen2026-09-22T05:04:18-07:00Radiofrequency Ablation: A Minimally Invasive Alternative for Thyroid Nodules Post-Lobectomy https://news.medxy.ai/zh/cvemp-vhit-discrepancy/Medxy AIzh2026-09-22T05:03:37-07:00cVEMP与后半规管vHIT为何常不一致：1770只耳研究揭示前庭诊断新视角 https://news.medxy.ai/ja/vemp-vhit-comparison/Medxy AIja2026-09-22T05:03:13-07:00頸部VEMPと後半規管vHITは本当に同じ機能を見ているのか？―1770耳の解析から見えた前庭診断の新たな示唆 https://news.medxy.ai/vi/cvemp-vhit-difference/Medxy AIvi2026-09-22T05:02:48-07:00Sự phân ly chức năng giữa cVEMP cổ và vHIT ống bán khuyên sau: gợi ý mới cho chẩn đoán tiền đình trên 1770 tai không chọn lọc https://news.medxy.ai/functional-dissociation-of-cervical-vemp-and-posterior-canal-vhit-implications-for-vestibular-diagnostics-in-1770-unselected-ears/Medxy AIen2026-09-22T05:02:24-07:00Functional Dissociation of Cervical VEMP and Posterior Canal vHIT: Implications for Vestibular Diagnostics in 1770 Unselected Ears https://news.medxy.ai/zh/thyroid-compression-symptoms-2/Medxy AIzh2026-09-22T05:01:37-07:00甲状腺压迫性症状：优化诊断与治疗以改善预后 https://news.medxy.ai/ja/76103-2/Medxy AIja2026-09-22T05:01:16-07:00甲状腺による圧迫症状：予後改善に向けた診断と治療の最適化 https://news.medxy.ai/vi/thyroid-compression-symptoms/Medxy AIvi2026-09-22T05:00:51-07:00Triệu chứng chèn ép do tuyến giáp: Tối ưu hóa chẩn đoán và điều trị để cải thiện kết cục https://news.medxy.ai/thyroid-compressive-symptoms-optimizing-diagnosis-and-management-for-improved-outcomes/Medxy AIen2026-09-22T05:00:25-07:00Thyroid Compressive Symptoms: Optimizing Diagnosis and Management for Improved Outcomes https://news.medxy.ai/zh/laennec-robotic-liver-surgery/Medxy AIzh2026-09-21T06:59:37-07:00Laennec技术：推动右侧机器人供肝切除标准化的新路径 https://news.medxy.ai/ja/76098-2/Medxy AIja2026-09-21T06:59:19-07:00ラエンネック（Laennec）法：ロボット支援下右側ドナー肝切除の標準化を推進する新たなアプローチ https://news.medxy.ai/vi/laennec-robotic-right-hepatectomy/Medxy AIvi2026-09-21T06:58:58-07:00Kỹ thuật Laennec: Hướng tới chuẩn hóa cắt gan phải ở người hiến bằng robot https://news.medxy.ai/the-laennec-technique-advancing-standardization-in-right-robotic-donor-hepatectomies/Medxy AIen2026-09-21T06:58:35-07:00The Laennec Technique: Advancing Standardization in Right Robotic Donor Hepatectomies https://news.medxy.ai/zh/robotic-left-pancreatectomy/Medxy AIzh2026-09-21T06:57:58-07:00机器人辅助左侧胰腺切除术学习曲线评估：一项国际多中心研究中的安全性与肿瘤学结局 https://news.medxy.ai/ja/robotic-left-pancreatectomy-2/Medxy AIja2026-09-21T06:57:38-07:00ロボット支援左側膵切除術の学習曲線を検証する：国際多施設研究による安全性と腫瘍学的転帰 https://news.medxy.ai/vi/robotic-left-pancreatectomy-learning-curve/Medxy AIvi2026-09-21T06:57:09-07:00Đánh giá đường cong học tập của cắt tụy trái hỗ trợ bằng robot: an toàn và kết cục ung bướu trong một nghiên cứu đa trung tâm quốc tế https://news.medxy.ai/assessing-the-learning-curve-of-robotic-left-sided-pancreatectomy-safety-and-oncological-outcomes-in-a-multicenter-international-study/Medxy AIen2026-09-21T06:56:47-07:00Assessing the Learning Curve of Robotic Left-Sided Pancreatectomy: Safety and Oncological Outcomes in a Multicenter International Study https://news.medxy.ai/zh/reduce-coronary-perfusion-risk/Medxy AIzh2026-09-21T06:56:03-07:00降低生物瓣主动脉根部置换中冠状动脉灌注不良风险的策略 https://news.medxy.ai/ja/coronary-flow-strategy/Medxy AIja2026-09-21T06:55:38-07:00生体人工弁大動脈基部置換における冠灌流障害を抑える戦略 https://news.medxy.ai/vi/reducing-coronary-ischemia/Medxy AIvi2026-09-21T06:55:12-07:00Chiến lược giảm thiểu thiếu máu tưới máu vành trong thay gốc động mạch chủ bằng van sinh học https://news.medxy.ai/strategies-to-minimize-coronary-malperfusion-in-bioprosthetic-aortic-root-replacement/Medxy AIen2026-09-21T06:54:48-07:00Strategies to Minimize Coronary Malperfusion in Bioprosthetic Aortic Root Replacement https://news.medxy.ai/zh/trauma-communication-gap/Medxy AIzh2026-09-21T06:54:04-07:00创伤救治中的沟通鸿沟：评估创伤复苏室内的创伤知情沟通 https://news.medxy.ai/ja/trauma-informed-communication/Medxy AIja2026-09-21T06:53:46-07:00外傷ベイにおけるトラウマ配慮型コミュニケーションを検証する：外傷ケアのギャップを埋める視点 https://news.medxy.ai/vi/trauma-care-communication/Medxy AIvi2026-09-21T06:53:20-07:00Thu hẹp khoảng cách trong chăm sóc chấn thương: Đánh giá giao tiếp theo hướng lưu ý đến sang chấn tại khu cấp cứu chấn thương https://news.medxy.ai/bridging-gaps-in-trauma-care-assessing-trauma-informed-communication-in-the-trauma-bay/Medxy AIen2026-09-21T06:52:55-07:00Bridging Gaps in Trauma Care: Assessing Trauma-Informed Communication in the Trauma Bay https://news.medxy.ai/zh/robotic-vs-laparoscopic-cholecystectomy-2/Medxy AIzh2026-09-21T06:52:11-07:00机器人胆囊切除术还是腹腔镜胆囊切除术？安全性、疗效与成本的权衡及新型风险计算器 https://news.medxy.ai/ja/robotic-vs-laparoscopic/Medxy AIja2026-09-21T06:51:51-07:00ロボット支援か腹腔鏡下か：新規リスク算出ツールでみる胆嚢摘出術の安全性・有効性・費用の最適な釣り合い https://news.medxy.ai/vi/robotic-gallbladder-surgery-2/Medxy AIvi2026-09-21T06:51:24-07:00Cắt túi mật bằng robot hay nội soi: Cân bằng an toàn, hiệu quả và chi phí với một công cụ dự đoán nguy cơ mới https://news.medxy.ai/robotic-versus-laparoscopic-cholecystectomy-balancing-safety-efficacy-and-cost-with-a-novel-risk-calculator/Medxy AIen2026-09-21T06:51:03-07:00Robotic Versus Laparoscopic Cholecystectomy: Balancing Safety, Efficacy, and Cost with a Novel Risk Calculator https://news.medxy.ai/zh/opioid-prescription-optimization/Medxy AIzh2026-09-21T06:50:21-07:00腹腔癌症术后阿片类药物出院处方如何优化：5倍乘数模型与三层模型的比较 https://news.medxy.ai/ja/optimize-opioid-prescription/Medxy AIja2026-09-21T06:50:03-07:00腹腔内がん手術後の退院時オピオイド処方を最適化する：5倍乗数モデルと3段階モデルの比較 https://news.medxy.ai/vi/opioid-prescription-optimization-2/Medxy AIvi2026-09-21T06:49:41-07:00Tối ưu hóa kê đơn opioid sau phẫu thuật ung thư trong ổ bụng: So sánh mô hình nhân 5 và mô hình 3 bậc https://news.medxy.ai/optimizing-postoperative-opioid-prescriptions-after-intra-abdominal-cancer-surgery-comparing-the-5x-multiplier-and-3-tier-models/Medxy AIen2026-09-21T06:49:23-07:00Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models https://news.medxy.ai/zh/rhd-antibody-formation/Medxy AIzh2026-09-21T06:48:45-07:00Rh(D) 阳性全血与 Rh(D) 阴性红细胞：创伤复苏后早期同种抗体形成的发生率及其意义 https://news.medxy.ai/ja/rh-positive-vs-rh-negative-blood/Medxy AIja2026-09-21T06:48:19-07:00外傷蘇生におけるRh(D)陽性全血とRh(D)陰性赤血球製剤：早期同種抗体形成の発生率と臨床的意義 https://news.medxy.ai/vi/antibody-formation-rates/Medxy AIvi2026-09-21T06:47:55-07:00Tỷ lệ và ý nghĩa của sự hình thành kháng thể bất đồng nhóm sớm sau hồi sức chấn thương bằng máu toàn phần Rh(D)+ so với hồng cầu Rh(D)- https://news.medxy.ai/incidence-and-implications-of-early-alloantibody-formation-after-trauma-resuscitation-with-rhd-whole-blood-versus-rhd-red-blood-cells/Medxy AIen2026-09-21T06:47:32-07:00Incidence and Implications of Early Alloantibody Formation After Trauma Resuscitation With Rh(D)+ Whole Blood Versus Rh(D)- Red Blood Cells https://news.medxy.ai/zh/gist-exon11-surgery/Medxy AIzh2026-09-21T06:46:47-07:00KIT 外显子 11 突变型 GIST 何时手术更合适？新辅助伊马替尼后影像学与病理学反应的启示 https://news.medxy.ai/ja/optimal-surgery-timing-gist/Medxy AIja2026-09-21T06:46:24-07:00KIT exon 11変異GISTにおける最適手術時期：ネオアジュバントimatinib後の画像評価と病理統合評価からみた示唆 https://news.medxy.ai/vi/optimal-gist-surgery/Medxy AIvi2026-09-21T06:45:55-07:00Thời điểm phẫu thuật tối ưu trong GIST đột biến KIT exon 11: Góc nhìn từ đáp ứng tích hợp hình ảnh và giải phẫu bệnh sau imatinib tân bổ trợ https://news.medxy.ai/optimal-surgical-timing-in-kit-exon-11-mutant-gist-insights-from-radiographic-and-pathology-integrated-responses-after-neoadjuvant-imatinib/Medxy AIen2026-09-21T06:45:31-07:00Optimal Surgical Timing in KIT Exon 11-Mutant GIST: Insights from Radiographic and Pathology-Integrated Responses After Neoadjuvant Imatinib https://news.medxy.ai/zh/avutometinib-defactinib-safety/Medxy AIzh2026-09-21T06:44:49-07:00复发性低级别浆液性卵巢癌中 Avutometinib 联合 Defactinib 的持久疗效与安全性：基于 ENGOT-OV60/GOG-3052/RAMP 201 2 年随访的解析 https://news.medxy.ai/ja/avutometinib-defactinib-ovarian-cancer/Medxy AIja2026-09-21T06:44:26-07:00再発低悪性度漿液性卵巣癌に対するAvutometinib＋Defactinibの持続的有効性と安全性：ENGOT-OV60/GOG-3052/RAMP 201の2年追跡解析 https://news.medxy.ai/vi/76057-2/Medxy AIvi2026-09-21T06:44:01-07:00Hiệu quả lâu dài và độ an toàn của Avutometinib kết hợp với Defactinib trong điều trị ung thư buồng trứng thể tuyến thanh dịch độ thấp tái phát: Phân tích dựa trên theo dõi 2 năm từ nghiên cứu ENGOT-OV60/GOG-3052/RAMP 201 https://news.medxy.ai/durable-efficacy-and-safety-of-avutometinib-plus-defactinib-in-recurrent-low-grade-serous-ovarian-cancer-insights-from-a-2-year-engot-ov60-gog-3052-ramp-201-follow-up/Medxy AIen2026-09-21T06:43:33-07:00Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up https://news.medxy.ai/zh/liver-cirrhosis-fall-prevention/Medxy AIzh2026-09-21T06:42:42-07:00乳果糖序贯联用 TeleTai-Chi：肝硬化患者跌倒预防的新策略 https://news.medxy.ai/ja/fall-prevention-cirrhosis/Medxy AIja2026-09-21T06:42:21-07:00肝硬変の転倒予防に挑む：ラクツロースと TeleTai-Chi を段階的に用いた LiveSMART 試験の知見 https://news.medxy.ai/vi/76052-2/Medxy AIvi2026-09-21T06:41:58-07:00Sử dụng tuần tự Lactulose và Tele-Tai Chi: Một chiến lược mới nhằm phòng ngừa té ngã ở bệnh nhân xơ gan https://news.medxy.ai/sequential-lactulose-and-teletai-chi-to-prevent-falls-in-cirrhosis-insights-from-the-livesmart-trial/Medxy AIen2026-09-21T06:41:31-07:00Sequential Lactulose and TeleTai-Chi to Prevent Falls in Cirrhosis: Insights from the LiveSMART Trial https://news.medxy.ai/zh/gut-microbiome-liver-cancer-2/Medxy AIzh2026-09-21T06:40:43-07:00肠道微生物组动态变化有望提升晚期肝癌免疫治疗获益预测 https://news.medxy.ai/ja/gut-microbiome-liver-cancer/Medxy AIja2026-09-21T06:40:22-07:00進行性肝癌の免疫療法成績を高める腸内マイクロバイオームの動的変化 https://news.medxy.ai/vi/gut-microbiome-therapy/Medxy AIvi2026-09-21T06:39:56-07:00Biến đổi động của hệ vi sinh đường ruột giúp nâng cao kết quả miễn dịch trị liệu ở ung thư gan giai đoạn tiến xa https://news.medxy.ai/dynamic-gut-microbiome-changes-enhance-immunotherapy-outcomes-in-advanced-liver-cancer/Medxy AIen2026-09-21T06:39:29-07:00Dynamic Gut Microbiome Changes Enhance Immunotherapy Outcomes in Advanced Liver Cancer https://news.medxy.ai/zh/hbv-immunosuppressive-macrophages/Medxy AIzh2026-09-21T06:38:48-07:00HBV诱导的免疫抑制性巨噬细胞：驱动慢性乙型肝炎持续存在的代谢与表观遗传通路 https://news.medxy.ai/ja/hbv-induced-macrophages/Medxy AIja2026-09-21T06:38:24-07:00HBVが誘導する免疫抑制性マクロファージ：慢性B型肝炎の持続を支える代謝・エピジェネティック経路 https://news.medxy.ai/vi/76042-2/Medxy AIvi2026-09-21T06:37:58-07:00Đại thực bào ức chế miễn dịch do HBV: Các con đường chuyển hóa và biểu di truyền thúc đẩy sự tồn tại dai dẳng của viêm gan B mạn tính https://news.medxy.ai/hbv-induced-immunosuppressive-macrophages-metabolic-and-epigenetic-pathways-driving-chronic-hepatitis-b-persistence/Medxy AIen2026-09-21T06:37:29-07:00HBV-Induced Immunosuppressive Macrophages: Metabolic and Epigenetic Pathways Driving Chronic Hepatitis B Persistence https://news.medxy.ai/zh/pancreatitis-pain-treatment/Medxy AIzh2026-09-21T06:36:44-07:00非肠溶包衣胰酶治疗慢性胰腺炎疼痛：一项高质量随机试验带来的启示 https://news.medxy.ai/ja/pancreatitis-pain-relief/Medxy AIja2026-09-21T06:36:20-07:00慢性膵炎の疼痛緩和に対する非腸溶性膵酵素療法を検証する：堅牢な無作為化試験からの知見 https://news.medxy.ai/vi/pancreatic-enzyme-therapy-pain/Medxy AIvi2026-09-21T06:35:53-07:00Đánh giá liệu pháp enzym tụy không bao tan ruột trong giảm đau do viêm tụy mạn: dữ liệu từ một thử nghiệm ngẫu nhiên quy mô lớn https://news.medxy.ai/evaluating-non-enteric-coated-pancreatic-enzyme-therapy-for-pain-relief-in-chronic-pancreatitis-insights-from-a-robust-randomized-trial/Medxy AIen2026-09-21T06:35:30-07:00Evaluating Non-Enteric-Coated Pancreatic Enzyme Therapy for Pain Relief in Chronic Pancreatitis: Insights from a Robust Randomized Trial https://news.medxy.ai/zh/microbiome-therapy-advances/Medxy AIzh2026-09-21T06:34:46-07:00精准微生物组治疗新进展：Faecalibacterium prausnitzii EXL01 预防多次复发性艰难拟梭菌感染 https://news.medxy.ai/ja/microbiome-treatment-clostridioides-prevention/Medxy AIja2026-09-21T06:34:21-07:00精密マイクロバイオーム治療の新展開：多発再発性 Clostridioides difficile 感染症予防における Faecalibacterium prausnitzii EXL01 https://news.medxy.ai/vi/76032-2/Medxy AIvi2026-09-21T06:33:53-07:00Faecalibacterium prausnitzii EXL01 để phòng ngừa tái phát nhiễm khuẩn Clostridioides difficile https://news.medxy.ai/precision-microbiome-therapeutics-faecalibacterium-prausnitzii-exl01-for-prevention-of-multiple-recurrent-clostridioides-difficile-infection/Medxy AIen2026-09-21T06:33:27-07:00Precision Microbiome Therapeutics: Faecalibacterium prausnitzii EXL01 for Prevention of Multiple-Recurrent Clostridioides difficile Infection https://news.medxy.ai/zh/cdkl5-eeg-seizures/Medxy AIzh2026-09-21T06:32:23-07:00早期 CDKL5 缺陷障碍中的 EEG 演变与发作特征：对发育结局的启示 https://news.medxy.ai/ja/cdkl5-eeg-seizures-2/Medxy AIja2026-09-21T06:31:59-07:00CDKL5欠損症乳幼児におけるEEGの推移と発作特徴：発達予後への示唆 https://news.medxy.ai/vi/cdkl5-seizure-progress/Medxy AIvi2026-09-21T06:31:34-07:00Diễn tiến EEG và đặc điểm cơn co giật trong giai đoạn sớm của rối loạn thiếu hụt CDKL5: hàm ý đối với kết cục phát triển https://news.medxy.ai/eeg-evolution-and-seizure-characteristics-in-early-cdkl5-deficiency-disorder-implications-for-developmental-outcomes/Medxy AIen2026-09-21T06:31:11-07:00EEG Evolution and Seizure Characteristics in Early CDKL5 Deficiency Disorder: Implications for Developmental Outcomes https://news.medxy.ai/zh/veterans-explosion-health/Medxy AIzh2026-09-21T06:30:27-07:00退伍军人军事爆炸暴露的长期健康影响：来自 Millennium Cohort Study 的启示 https://news.medxy.ai/ja/military-blast-exposure-risks/Medxy AIja2026-09-21T06:30:04-07:00軍務中の爆風曝露は退役後の健康にどう影響するか：ミレニアム・コホート研究が示す長期的リスク https://news.medxy.ai/vi/long-term-health-effects/Medxy AIvi2026-09-21T06:29:37-07:00Ảnh hưởng sức khỏe lâu dài của phơi nhiễm nổ trong quân đội ở cựu chiến binh: Những phát hiện từ Millennium Cohort Study https://news.medxy.ai/long-term-health-impacts-of-military-blast-exposure-on-veterans-insights-from-the-millennium-cohort-study/Medxy AIen2026-09-21T06:29:12-07:00Long-Term Health Impacts of Military Blast Exposure on Veterans: Insights from the Millennium Cohort Study https://news.medxy.ai/zh/pituitary-adenoma-subtypes/Medxy AIzh2026-09-21T06:28:30-07:00垂体腺瘤的组织学亚型：对肢端肥大症手术结局与疾病控制的影响 https://news.medxy.ai/ja/pituitary-adenoma-subtypes-2/Medxy AIja2026-09-21T06:28:04-07:00下垂体腺腫の組織学的サブタイプ：先端巨大症における手術成績と疾患コントロールへの影響 https://news.medxy.ai/vi/pituitary-adenoma-classification/Medxy AIvi2026-09-21T06:27:38-07:00Phân nhóm mô học của u tuyến yên: Vai trò trong kết cục phẫu thuật và kiểm soát bệnh ở bệnh to đầu chi https://news.medxy.ai/histological-subtypes-of-pituitary-adenomas-their-role-in-acromegaly-surgical-outcomes-and-disease-control/Medxy AIen2026-09-21T06:27:09-07:00Histological Subtypes of Pituitary Adenomas: Their Role in Acromegaly Surgical Outcomes and Disease Control https://news.medxy.ai/zh/anaplastic-thyroid-cancer-chemotherapy/Medxy AIzh2026-09-21T06:26:22-07:00德国多中心注册研究：间变性甲状腺癌一线化疗策略的疗效评估 https://news.medxy.ai/ja/undifferentiated-thyroid-cancer-chemotherapy/Medxy AIja2026-09-21T06:25:59-07:00未分化甲状腺がんの一次化学療法を再考する：ドイツ多施設レジストリからの知見 https://news.medxy.ai/vi/thyroid-cancer-treatment-2/Medxy AIvi2026-09-21T06:25:37-07:00Đánh giá chiến lược hóa trị tuyến đầu trong ung thư tuyến giáp không biệt hóa: Góc nhìn từ một đăng ký đa trung tâm tại Đức https://news.medxy.ai/evaluating-first-line-chemotherapy-strategies-in-anaplastic-thyroid-cancer-insights-from-a-german-multicenter-registry/Medxy AIen2026-09-21T06:25:15-07:00Evaluating First-Line Chemotherapy Strategies in Anaplastic Thyroid Cancer: Insights from a German Multicenter Registry https://news.medxy.ai/zh/cushing-disease-remission/Medxy AIzh2026-09-21T06:24:27-07:00库欣病长期缓解后血浆蛋白异常仍持续存在：对发病风险与监测的启示 https://news.medxy.ai/ja/cushing-disease-biomarkers/Medxy AIja2026-09-21T06:24:02-07:00クッシング病の長期寛解後も残る血漿タンパク質異常――罹患リスクと経過観察への示唆 https://news.medxy.ai/vi/cushing-syndrome-longterm/Medxy AIvi2026-09-21T06:23:32-07:00Bệnh Cushing sau thuyên giảm lâu dài: các bất thường protein huyết tương dai dẳng và ý nghĩa đối với bệnh tật, theo dõi https://news.medxy.ai/persistent-plasma-protein-alterations-after-long-term-remission-in-cushings-disease-implications-for-morbidity-and-monitoring/Medxy AIen2026-09-21T06:23:07-07:00Persistent Plasma Protein Alterations After Long-Term Remission in Cushing’s Disease: Implications for Morbidity and Monitoring https://news.medxy.ai/zh/type-1-diabetes-trajectories/Medxy AIzh2026-09-21T06:22:20-07:001型糖尿病成人的长期血糖轨迹：一项3年多中心CGM研究的启示 https://news.medxy.ai/ja/type-1-diabetes-trends/Medxy AIja2026-09-21T06:21:56-07:001型糖尿病成人における血糖推移の縦断解析：3年間の多施設CGM研究からの示唆 https://news.medxy.ai/vi/vertical-glucose-trajectory/Medxy AIvi2026-09-21T06:21:29-07:00Quỹ đạo đường huyết theo chiều dọc ở người lớn mắc đái tháo đường típ 1: Góc nhìn từ nghiên cứu đa trung tâm CGM kéo dài 3 năm https://news.medxy.ai/longitudinal-glycemic-trajectories-in-adults-with-type-1-diabetes-insights-from-a-three-year-multicenter-cgm-study/Medxy AIen2026-09-21T06:21:04-07:00Longitudinal Glycemic Trajectories in Adults with Type 1 Diabetes: Insights from a Three-Year Multicenter CGM Study https://news.medxy.ai/zh/pregnancy-pcos-outcomes/Medxy AIzh2026-09-21T06:20:15-07:00妊娠期多内分泌代谢性卵巢综合征与母婴结局：一项嵌套前瞻性队列研究的启示 https://news.medxy.ai/ja/pcos-pregnancy-effects/Medxy AIja2026-09-21T06:19:52-07:00妊娠中のポリ内分泌代謝性卵巣症候群が母体・新生児転帰に及ぼす影響：ネスト型前向きコホート研究からの知見 https://news.medxy.ai/vi/75973-2/Medxy AIvi2026-09-21T06:19:22-07:00Hội chứng buồng trứng đa nang trong thai kỳ và kết cục đối với mẹ và con https://news.medxy.ai/maternal-and-neonatal-outcomes-associated-with-polyendocrine-metabolic-ovarian-syndrome-during-pregnancy-insights-from-a-nested-prospective-cohort-study/Medxy AIen2026-09-21T06:18:57-07:00Maternal and Neonatal Outcomes Associated with Polyendocrine Metabolic Ovarian Syndrome During Pregnancy: Insights from a Nested Prospective Cohort Study https://news.medxy.ai/zh/diabetes-management-alerts/Medxy AIzh2026-09-21T06:18:10-07:00从预警到行动：借助电子健康记录提醒提升糖尿病自我管理转诊 https://news.medxy.ai/ja/alert-action-diabetes/Medxy AIja2026-09-21T06:17:50-07:00アラートを行動へ：電子カルテのアラートで糖尿病自己管理支援紹介を強化する https://news.medxy.ai/vi/diabetes-care-alerts/Medxy AIvi2026-09-21T06:17:30-07:00Từ cảnh báo đến hành động: Nâng cao chuyển tuyến giáo dục tự quản lý đái tháo đường qua cảnh báo trên hồ sơ sức khỏe điện tử https://news.medxy.ai/from-alert-to-action-enhancing-diabetes-self-management-referrals-through-electronic-health-record-alerts/Medxy AIen2026-09-21T06:17:08-07:00From Alert to Action: Enhancing Diabetes Self-Management Referrals Through Electronic Health Record Alerts https://news.medxy.ai/zh/semaglutide-efficacy-safety/Medxy AIzh2026-09-21T06:16:28-07:00司美格鲁肽在不同虚弱状态下的疗效与安全性：基于SELECT随机临床试验事后分析的启示 https://news.medxy.ai/ja/semaglutide-efficacy-safety-2/Medxy AIja2026-09-21T06:16:02-07:00フレイル状態別にみたセマグルチドの有効性と安全性：SELECTランダム化臨床試験の事後解析からの示唆 https://news.medxy.ai/vi/semaglutide-frailty/Medxy AIvi2026-09-21T06:15:33-07:00Semaglutide: Hiệu quả và độ an toàn theo tình trạng frailty từ phân tích hậu kiểm thử nghiệm lâm sàng ngẫu nhiên SELECT https://news.medxy.ai/efficacy-and-safety-of-semaglutide-according-to-frailty-status-insights-from-the-select-randomized-clinical-trial-post-hoc-analysis/Medxy AIen2026-09-21T06:15:04-07:00Efficacy and Safety of Semaglutide According to Frailty Status: Insights from the SELECT Randomized Clinical Trial Post Hoc Analysis https://news.medxy.ai/ja/whole-grains-metabolic-risk/Medxy AIja2026-09-21T05:46:13-07:00全粒穀物の摂取は心代謝リスクを下げるか：ランダム化試験のメタ解析 https://news.medxy.ai/vi/whole-grains-heart-risk/Medxy AIvi2026-09-21T05:45:50-07:00Ngũ cốc nguyên hạt và nguy cơ tim mạch – chuyển hóa: Phân tích tổng hợp từ các thử nghiệm ngẫu nhiên https://news.medxy.ai/whole-grain-consumption-and-cardiometabolic-risk-a-meta-analysis-of-randomized-trials/Medxy AIen2026-09-21T05:45:25-07:00Whole-grain Consumption and Cardiometabolic Risk: A Meta-analysis of Randomized Trials https://news.medxy.ai/zh/75928-2/Medxy AIzh2026-09-21T05:44:35-07:00心脏压力负荷时代谢应激可能加剧蒽环类药物的心脏毒性 https://news.medxy.ai/ja/anthracycline-cardiotoxicity/Medxy AIja2026-09-21T05:44:02-07:00圧負荷心における代謝ストレスが増幅するアントラサイクリン心毒性：機序的理解と臨床的意義 https://news.medxy.ai/vi/anthracycline-heart-toxicity/Medxy AIvi2026-09-21T05:43:35-07:00Độc tính tim do anthracycline bị thúc đẩy bởi stress chuyển hóa ở tim quá tải áp lực: cơ chế và ý nghĩa lâm sàng https://news.medxy.ai/anthracycline-cardiotoxicity-exacerbated-by-metabolic-stress-in-pressure-overloaded-hearts-mechanistic-insights-and-clinical-implications/Medxy AIen2026-09-21T05:43:03-07:00Anthracycline Cardiotoxicity Exacerbated by Metabolic Stress in Pressure-Overloaded Hearts: Mechanistic Insights and Clinical Implications https://news.medxy.ai/zh/hpv16-head-neck-cancer/Medxy AIzh2026-09-21T05:42:19-07:00HPV16 阳性复发/转移性头颈癌迎来新希望：VERSATILE-002Ⅱ期研究揭示免疫联合治疗潜力 https://news.medxy.ai/ja/hpv16-recurrence-treatment/Medxy AIja2026-09-21T05:41:57-07:00HPV16陽性再発・転移性頭頸部癌で新規免疫療法併用に期待：VERSATILE-002第2相試験から見えた可能性 https://news.medxy.ai/vi/immune-combination-hpv16/Medxy AIvi2026-09-21T05:41:28-07:00Phối hợp miễn dịch mới cho kết quả khả quan ở ung thư đầu cổ tái phát/di căn dương tính HPV16: Góc nhìn từ thử nghiệm pha 2 VERSATILE-002 https://news.medxy.ai/novel-immunotherapy-combination-shows-promise-in-hpv16-positive-r-m-head-and-neck-cancer-insights-from-the-versatile-002-phase-2-trial/Medxy AIen2026-09-21T05:41:02-07:00Novel Immunotherapy Combination Shows Promise in HPV16-Positive R/M Head and Neck Cancer: Insights from the VERSATILE-002 Phase 2 Trial https://news.medxy.ai/zh/low-pdl1-head-neck-cancer/Medxy AIzh2026-09-21T05:40:15-07:00低 PD-L1 表达头颈鳞状细胞癌的免疫治疗：一项关于生存结局的荟萃分析洞见 https://news.medxy.ai/ja/pd-l1-low-headneck-cancer/Medxy AIja2026-09-21T05:39:46-07:00PD-L1低発現頭頸部扁平上皮癌における免疫療法：生存転帰を読み解くメタ解析の知見 https://news.medxy.ai/vi/75916-2/Medxy AIvi2026-09-21T05:39:12-07:00Liệu pháp miễn dịch trong ung thư biểu mô tế bào vảy vùng đầu cổ có biểu hiện PD-L1 thấp https://news.medxy.ai/immunotherapy-in-head-and-neck-squamous-cell-carcinoma-with-low-pd-l1-expression-a-meta-analytic-insight-into-survival-outcomes/Medxy AIen2026-09-21T05:38:48-07:00Immunotherapy in Head and Neck Squamous Cell Carcinoma with Low PD-L1 Expression: A Meta-Analytic Insight into Survival Outcomes https://news.medxy.ai/zh/at2-tgf-beta1-platelet-thrombosis/Medxy AIzh2026-09-21T05:14:03-07:00揭示血管紧张素Ⅱ驱动的TGF-β1在高血压中增强血小板PAR4表达及血栓风险中的作用 https://news.medxy.ai/ja/angiotensin-tgf-beta-thrombosis/Medxy AIja2026-09-21T05:13:42-07:00アンジオテンシンII―TGF-β1軸が血小板PAR4を高める機序と高血圧における血栓リスクの新知見 https://news.medxy.ai/vi/tgf-beta1-par4-thrombosis/Medxy AIvi2026-09-21T05:13:19-07:00Khám phá vai trò của TGF-β1 do Angiotensin II dẫn dắt trong việc làm tăng biểu hiện PAR4 trên tiểu cầu và nguy cơ huyết khối ở tăng huyết áp https://news.medxy.ai/angiotensin-tgf-beta-thrombosis-2/Medxy AIen2026-09-21T05:12:54-07:00Unveiling the Role of Angiotensin II-Driven TGF-β1 in Enhancing Platelet PAR4 Expression and Thrombotic Risk in Hypertension